AYER, Mass.--(BUSINESS WIRE)--Cambrooke Therapeutics Inc., a leader in therapeutic nutrition for inborn errors of metabolism and ketogenic diet therapy, is pleased to announce a new and improved Glytactin™ Complete Bar, a medical food for the dietary management of Phenylketonuria (PKU).
The new and improved Glytactin™ Complete Bar contains glytactin with glycomacropeptide (GMP) with all the benefits of natural whole protein. The bars have the same nutrition as the previous bars, are still made in both 10g and 15g protein equivalents (PE) packages and are available in both Chocolate Peanut Butter and Fruit Frenzy flavor varieties.
The new version has enhancements that make the bar more enjoyable and convenient. First, the Glytactin™ Complete Bar is now thinner, making it less chewy. In addition, the Glytactin™ Complete Bar has been separated into 5g PE mini-bars; the10g PE package contains two individual 5g bars. The 15g PE package contains three individual 5g bars.
Glytactin™ Complete Bars are a great way to meet daily protein requirements as part of a complete PKU diet program. The convenient package format makes it ideal for use at school, work, vacations, sporting activities or any time simple convenience is desired. And now, with 5g mini-bar portions, one Glytactin™ Complete Bar can more easily be enjoyed at different times in the day.
“The new Complete Bars taste great and are so much easier to eat,” says Tiffany J., a child with PKU.
Tiffany’s mom adds, “The old Complete Bar was too much for Tiffany to have at lunch, so I love being able to send her to school with one mini bar, saving the other portion for when she gets home from school.”
About Cambrooke Therapeutics – Founded in 2000, Cambrooke Therapeutics is a private equity-backed, Massachusetts-based therapeutic nutrition company and global provider of medical nutrition products for patients with serious unmet medical needs. The company works with physicians and researchers from around the world to develop, test and commercialize products that are focused on inborn errors of metabolism and intractable epilepsy. More information is available at www.cambrooketherapeutics.com.